Amphastar Pharma (AMPH) Tops Q3 EPS by 2c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $63.55 million versus the consensus estimate of $55.78 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance